Abstract

Chemotherapy has been used for treatment of breast cancer but with limited success. We characterized the effects of bcl-2 antisense and cisplatin combination therapy in two human isogenic breast carcinoma cells p53(+)MCF-7 and p53(-)MCF-7/E6. The transferrin-facilitated lipofection strategy we have developed yielded same transfection efficiency in both cells. Bcl-2 antisense delivered with this strategy significantly induced more cell death, apoptosis, and cytochrome c release in MCF-7/E6 than in MCF-7, but did not affect Fas level in both cells and activated caspase-8 equally. Cisplatin exerted same effects on cell viability and apoptosis in both cells, but released smaller amounts of cytochrome c while activated more caspase-8 in MCF-7/E6. The combination treatment yielded greater effects on cell viability, apoptosis, cytochrome c release, and caspase-8 activation than individual treatments in both cells although p53(-) cells were more sensitive. The potentiated activation of caspase-8 in the combination treatment suggested that caspase-8-mediated (but cytochrome c-independent) apoptotic pathway is the major contributor of the enhanced cell killing. Thus, bcl-2 antisense delivered with transferrin- facilitated lipofection can achieve the efficacy of killing breast cancer cells and sensitizing them to chemotherapy. Bcl-2 antisense and cisplatin combination treatment is a potentially useful therapeutic strategy for breast cancer irrespective of p53 status.

Original languageEnglish (US)
Pages (from-to)999-1011
Number of pages13
JournalJournal of Biomedical Science
Volume12
Issue number6
DOIs
StatePublished - Dec 1 2005

Fingerprint

Caspase 8
Cisplatin
Cytochromes c
Cells
Breast Neoplasms
Chemotherapy
Transferrin
Apoptosis
Chemical activation
Therapeutics
Cell Survival
Cell death
Drug Therapy
MCF-7 Cells
Transfection
Cell Death

Keywords

  • Apoptosis
  • Bcl-2 antisense
  • Breast cancer
  • Caspase 8
  • Cisplatin
  • Cytochrome c
  • Facilitated lipofection gene delivery strategy
  • Fas
  • Liposome
  • p53

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. / Basma, Hesham E; El-Refaey, Hesham; Sgagias, Magdalene K.; Cowan, Kenneth H; Luo, Xu; Cheng, Pi-Wan.

In: Journal of Biomedical Science, Vol. 12, No. 6, 01.12.2005, p. 999-1011.

Research output: Contribution to journalArticle

@article{172613a5d5dd4c4c99918d0c9399270d,
title = "BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53",
abstract = "Chemotherapy has been used for treatment of breast cancer but with limited success. We characterized the effects of bcl-2 antisense and cisplatin combination therapy in two human isogenic breast carcinoma cells p53(+)MCF-7 and p53(-)MCF-7/E6. The transferrin-facilitated lipofection strategy we have developed yielded same transfection efficiency in both cells. Bcl-2 antisense delivered with this strategy significantly induced more cell death, apoptosis, and cytochrome c release in MCF-7/E6 than in MCF-7, but did not affect Fas level in both cells and activated caspase-8 equally. Cisplatin exerted same effects on cell viability and apoptosis in both cells, but released smaller amounts of cytochrome c while activated more caspase-8 in MCF-7/E6. The combination treatment yielded greater effects on cell viability, apoptosis, cytochrome c release, and caspase-8 activation than individual treatments in both cells although p53(-) cells were more sensitive. The potentiated activation of caspase-8 in the combination treatment suggested that caspase-8-mediated (but cytochrome c-independent) apoptotic pathway is the major contributor of the enhanced cell killing. Thus, bcl-2 antisense delivered with transferrin- facilitated lipofection can achieve the efficacy of killing breast cancer cells and sensitizing them to chemotherapy. Bcl-2 antisense and cisplatin combination treatment is a potentially useful therapeutic strategy for breast cancer irrespective of p53 status.",
keywords = "Apoptosis, Bcl-2 antisense, Breast cancer, Caspase 8, Cisplatin, Cytochrome c, Facilitated lipofection gene delivery strategy, Fas, Liposome, p53",
author = "Basma, {Hesham E} and Hesham El-Refaey and Sgagias, {Magdalene K.} and Cowan, {Kenneth H} and Xu Luo and Pi-Wan Cheng",
year = "2005",
month = "12",
day = "1",
doi = "10.1007/s11373-005-9025-y",
language = "English (US)",
volume = "12",
pages = "999--1011",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53

AU - Basma, Hesham E

AU - El-Refaey, Hesham

AU - Sgagias, Magdalene K.

AU - Cowan, Kenneth H

AU - Luo, Xu

AU - Cheng, Pi-Wan

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Chemotherapy has been used for treatment of breast cancer but with limited success. We characterized the effects of bcl-2 antisense and cisplatin combination therapy in two human isogenic breast carcinoma cells p53(+)MCF-7 and p53(-)MCF-7/E6. The transferrin-facilitated lipofection strategy we have developed yielded same transfection efficiency in both cells. Bcl-2 antisense delivered with this strategy significantly induced more cell death, apoptosis, and cytochrome c release in MCF-7/E6 than in MCF-7, but did not affect Fas level in both cells and activated caspase-8 equally. Cisplatin exerted same effects on cell viability and apoptosis in both cells, but released smaller amounts of cytochrome c while activated more caspase-8 in MCF-7/E6. The combination treatment yielded greater effects on cell viability, apoptosis, cytochrome c release, and caspase-8 activation than individual treatments in both cells although p53(-) cells were more sensitive. The potentiated activation of caspase-8 in the combination treatment suggested that caspase-8-mediated (but cytochrome c-independent) apoptotic pathway is the major contributor of the enhanced cell killing. Thus, bcl-2 antisense delivered with transferrin- facilitated lipofection can achieve the efficacy of killing breast cancer cells and sensitizing them to chemotherapy. Bcl-2 antisense and cisplatin combination treatment is a potentially useful therapeutic strategy for breast cancer irrespective of p53 status.

AB - Chemotherapy has been used for treatment of breast cancer but with limited success. We characterized the effects of bcl-2 antisense and cisplatin combination therapy in two human isogenic breast carcinoma cells p53(+)MCF-7 and p53(-)MCF-7/E6. The transferrin-facilitated lipofection strategy we have developed yielded same transfection efficiency in both cells. Bcl-2 antisense delivered with this strategy significantly induced more cell death, apoptosis, and cytochrome c release in MCF-7/E6 than in MCF-7, but did not affect Fas level in both cells and activated caspase-8 equally. Cisplatin exerted same effects on cell viability and apoptosis in both cells, but released smaller amounts of cytochrome c while activated more caspase-8 in MCF-7/E6. The combination treatment yielded greater effects on cell viability, apoptosis, cytochrome c release, and caspase-8 activation than individual treatments in both cells although p53(-) cells were more sensitive. The potentiated activation of caspase-8 in the combination treatment suggested that caspase-8-mediated (but cytochrome c-independent) apoptotic pathway is the major contributor of the enhanced cell killing. Thus, bcl-2 antisense delivered with transferrin- facilitated lipofection can achieve the efficacy of killing breast cancer cells and sensitizing them to chemotherapy. Bcl-2 antisense and cisplatin combination treatment is a potentially useful therapeutic strategy for breast cancer irrespective of p53 status.

KW - Apoptosis

KW - Bcl-2 antisense

KW - Breast cancer

KW - Caspase 8

KW - Cisplatin

KW - Cytochrome c

KW - Facilitated lipofection gene delivery strategy

KW - Fas

KW - Liposome

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=30544432958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30544432958&partnerID=8YFLogxK

U2 - 10.1007/s11373-005-9025-y

DO - 10.1007/s11373-005-9025-y

M3 - Article

C2 - 16228292

AN - SCOPUS:30544432958

VL - 12

SP - 999

EP - 1011

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 6

ER -